Search clinical trials for: Pluvicto

Total 19 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Not yet recruiting

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization ((SEEtoTREAT))

Prostate Cancer | Advanced Cancer
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Dana-Farber Cancer Institute
Novartis

Not yet recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Maria Sklodowska-Curie National Research Institute...

Not yet recruiting

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial (LuRM_ACC/2023)

Adenoid Cystic Carcinoma

Poland
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
VA Office of Research and Development

Recruiting

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Prostate Cancer

United States
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Novartis Pharmaceuticals

Recruiting

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)

Prostatic Neoplasm

Korea, Republic of, Singapore, United States, Canada, Poland, Spain, Czechia
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
OncoC4, Inc.
Prostate Cancer Clinical Trials Consortium

Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (PRESERVE-006)

Metastatic Castration-resistant Prostate Cancer

United States
The Netherlands Cancer Institute
UMC Utrecht; Advanced Accelerator Applications

Recruiting

EBRT + Lu-PSMA for N1M0 Prostate Cancer (PROQURE-1)

Prostatic Neoplasm

Netherlands
Novartis Pharmaceuticals
Eckert & Ziegler Radiopharma GmbH

Recruiting

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Prostate Cancer

Japan
Novartis Pharmaceuticals
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.

Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)

Prostatic Neoplasms

United States, China, Canada, Spain, United Kingdom, Belgium, Japan, Taiwan, Germany, Singapore, Austria, Netherlands, Korea, Republic of, France, Switzerland, Denmark, Sweden, Poland, Czechia
Novartis Pharmaceuticals

Active, not recruiting

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)

Prostatic Neoplasms

Belgium, Canada, Spain, Germany, Austria, Netherlands, United Kingdom, United States, France, Switzerland, Sweden, Slovakia, Poland, Czechia
Canadian Cancer Trials Group
Endocyte; Prostate Cancer Canada

Active, not recruiting

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Prostate Cancer

Canada

Search clinical trials for: Pluvicto

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations